Fexagratinib

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameFexagratinib
Drug Alias NameAZD4547AZD-4547ABSK-091ABSK091
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 1 antagonistsFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 3 antagonists
TargetsFibroblast growth factor receptor 1Fibroblast growth factor receptor 2Fibroblast growth factor receptor 3
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursFoodborne Diseases +[35] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[21] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesABbisko Therapeutics Co LtdAstrazeneca PlcNational Cancer Institute +[4] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[32] 
Inactive IndicationsFoodborne DiseasesGastrointestinal DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A